These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3699143)

  • 1. [Effect of sulodexide on various metabolic risk factors in diabetic macroangiopathies].
    Pierfranceschi DG
    Farmaco Prat; 1986 Feb; 41(2):67-74. PubMed ID: 3699143
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease.
    Gaddi A; Galetti C; Illuminati B; Nascetti S
    J Int Med Res; 1996; 24(5):389-406. PubMed ID: 8895043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities].
    Utratová J; Mayer J; Elbl L; Vorlícek J; Prásek J
    Vnitr Lek; 1993 Jun; 39(6):575-80. PubMed ID: 8212613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The behavior of some metabolic and instrumental parameters in diabetics with arteriopathy of the lower extremities treated with increasing doses of glucuronyl-glycosaminoglycano-sulfate].
    Marigo S
    Clin Ter; 1980 Jun; 93(5):503-18. PubMed ID: 7428314
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus.
    Skrha J; Perusicová J; Kvasnicka J; Hilgertová J
    Sb Lek; 1998; 99(2):103-9. PubMed ID: 10536489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats.
    Andriuoli G; Mastacchi R; Barbanti M
    Thromb Res; 1984 Apr; 34(1):81-6. PubMed ID: 6729771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease.
    Castelluccio A; Bologna E
    Curr Med Res Opin; 1991; 12(5):325-31. PubMed ID: 2004545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulodexide and the microcirculatory component in microphlebopathies.
    Cospite M; Ferrara F; Cospite V; Palazzini E
    Curr Med Res Opin; 1992; 13(1):56-60. PubMed ID: 1468246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year course of oral sulodexide in the management of diabetic nephropathy.
    Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M
    J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosaminoglycan therapy for long-term diabetic complications?
    Gambaro G; Skrha J; Ceriello A
    Diabetologia; 1998 Aug; 41(8):975-9. PubMed ID: 9726602
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetes care needs evidence based interventions to reduce risk of vascular disease.
    Byrne CD; Wild SH
    BMJ; 2000 Jun; 320(7249):1554-5. PubMed ID: 10845947
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC
    Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of non-heparin glycosaminoglycans as therapeutic agents: II. A symposium. Chicago.
    Semin Thromb Hemost; 1991; 17 Suppl 2():137-245. PubMed ID: 1683007
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats.
    Salehi E; Khazaei M; Rashidi B
    Gen Physiol Biophys; 2012 Sep; 31(3):255-60. PubMed ID: 23047938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of sulodexide, a glycosaminoglycan, on albuminuria in diabetic patients].
    Perusicová J; Skrha J
    Vnitr Lek; 1997 Nov; 43(11):748-52. PubMed ID: 9650507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hydroxyproline indicators before and after treatment of diabetic angiopathies].
    Spesivtseva VG; Mamaeva GG; Starosel'tseva LK; Tulemisov EU; Bokaneva IA
    Ter Arkh; 1978; 50(1):93-7. PubMed ID: 635809
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and provider congruence.
    Zulkowski K; Coon P; Wittnam C
    Diabetes Care; 2003 Dec; 26(12):3358. PubMed ID: 14633835
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapies for diabetic dyslipidaemia.
    Bell DS; Al Badarin F; O'Keefe JH
    Diabetes Obes Metab; 2011 Apr; 13(4):313-25. PubMed ID: 21205114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.